Prospective, Observational, Longitudinal Study in Paediatric Patients With AD, Treated With Dupilumab in Spain
Status: Recruiting
Location: See all (15) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
This is a multicentre, prospective, non-interventional study that aims to describe the treatment patterns of in Atopic dermatitis (AD) patients aged 6 months to 11 years old in Spain: patients' characteristics, disease characteristics, prior treatments for and treatment prescription modalities. As well as to document the real-world effectiveness and safety of dupilumab during the two years of follow up. No diagnostic or therapeutic intervention outside of routine clinical practice will be applied.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 6 months
Maximum Age: 11
Healthy Volunteers: f
View:
• Male or female aged 6 months to 11 years old at baseline.
• Patients with severe Atopic dermatitis (AD) according to the investigator's assessment.
• Patients initiating dupilumab (in those patients initiated retrospectively 2 months before the start of the study, the baseline information must be correctly filled out in the medical records).
• Signed informed consent by the parent/legally acceptable representative and assent by the patient appropriate to the patient's age.
Locations
Other Locations
Spain
Investigational Site Number : 7240002
RECRUITING
Alicante
Investigational Site Number : 7240003
RECRUITING
Barcelona
Investigational Site Number : 7240006
RECRUITING
Esplugues De Llobregat
Investigational Site Number : 7240001
RECRUITING
Madrid
Investigational Site Number : 7240007
RECRUITING
Madrid
Investigational Site Number : 7240010
RECRUITING
Madrid
Investigational Site Number : 7240014
RECRUITING
Madrid
Investigational Site Number : 7240013
RECRUITING
Málaga
Investigational Site Number : 7240005
RECRUITING
Oviedo
Investigational Site Number : 7240012
RECRUITING
Palma
Investigational Site Number : 7240009
RECRUITING
San Cristóbal De La Laguna
Investigational Site Number : 7240004
RECRUITING
Santiago De Compostela
Investigational Site Number : 7240008
RECRUITING
Seville
Investigational Site Number : 7240016
RECRUITING
Valencia
Investigational Site Number : 7240011
RECRUITING
Zaragoza
Contact Information
Primary
Trial Transparency email recommended (Toll free for US & Canada)
Contact-us@sanofi.com
800-633-1610
Time Frame
Start Date:2024-11-14
Estimated Completion Date:2027-11-23
Participants
Target number of participants:150
Treatments
Dupilumab
The information will be collected during consultation as part of the patient's usual follow-up.